ES2116642T3 - Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol. - Google Patents

Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol.

Info

Publication number
ES2116642T3
ES2116642T3 ES95105766T ES95105766T ES2116642T3 ES 2116642 T3 ES2116642 T3 ES 2116642T3 ES 95105766 T ES95105766 T ES 95105766T ES 95105766 T ES95105766 T ES 95105766T ES 2116642 T3 ES2116642 T3 ES 2116642T3
Authority
ES
Spain
Prior art keywords
xantohumol
pharmaceutical composition
treat osteoporosis
osteoporosis containing
osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95105766T
Other languages
English (en)
Inventor
Hiroyasu Tobe
Kazuyuki Kitamura
Osamu Komiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Aventis Pharmaceuticals Inc
Original Assignee
Nippon Hoechst Marion Roussel Ltd
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Hoechst Marion Roussel Ltd, Hoechst Marion Roussel Inc filed Critical Nippon Hoechst Marion Roussel Ltd
Application granted granted Critical
Publication of ES2116642T3 publication Critical patent/ES2116642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN AGENTE TERAPEUTICO PARA OSTEOPOROSIS QUE COMPRENDE COMO UN INGREDIENTE ACTIVO XANTOHUMOL. EL XANTOHUMOL OBTENIDO DE EXTRACTOS DE LUPULO TIENE UNA ACTIVIDAD PARA INHIBIR LA RESORCION OSEA Y ES UTIL COMO UN AGENTE TERAPEUTICO PARA OSTEOPOROSIS.
ES95105766T 1994-04-21 1995-04-18 Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol. Expired - Lifetime ES2116642T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6082852A JPH07285856A (ja) 1994-04-21 1994-04-21 骨粗鬆症治療剤

Publications (1)

Publication Number Publication Date
ES2116642T3 true ES2116642T3 (es) 1998-07-16

Family

ID=13785904

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95105766T Expired - Lifetime ES2116642T3 (es) 1994-04-21 1995-04-18 Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol.

Country Status (14)

Country Link
US (1) US5679716A (es)
EP (1) EP0679393B1 (es)
JP (1) JPH07285856A (es)
KR (1) KR100350564B1 (es)
AT (1) ATE162073T1 (es)
AU (1) AU695696B2 (es)
CA (1) CA2147419A1 (es)
DE (1) DE69501419T2 (es)
DK (1) DK0679393T3 (es)
ES (1) ES2116642T3 (es)
FI (1) FI951856A (es)
HU (1) HUT71603A (es)
NO (1) NO951498L (es)
TW (1) TW284687B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008208A (en) * 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
DE19939350B4 (de) * 1999-08-19 2005-04-07 Plantextrakt Gmbh & Co. Kg Hopfenextrakt und Verfahren zu dessen Herstellung
CN100346776C (zh) * 2000-01-27 2007-11-07 宝生物工程株式会社 治疗剂
KR100842693B1 (ko) * 2000-04-10 2008-07-01 다카라 바이오 가부시키가이샤 치료제
US6352726B1 (en) * 2001-01-09 2002-03-05 S. S. Steiner, Inc. Method of killing protozoa
US20040156950A1 (en) * 2001-04-05 2004-08-12 Green Martin Richard Use of hop components in foods
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
ATE522207T1 (de) * 2002-02-14 2011-09-15 Kirin Brewery Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels
AU2002257721A1 (en) * 2002-04-24 2003-11-10 Unilever Plc Use of hop components in foods
DE10240065B4 (de) * 2002-08-30 2004-10-28 Hallertauer Hopfenveredlungsgesellschaft M.B.H. Verfahren zur Gewinnung von in Hopfen enthaltenem Xanthohumol und damit erhältlicher Xanthohumol-reicher Hopfenextrakt
ES2258200T3 (es) * 2002-12-18 2006-08-16 Dohler Gmbh Bebida que contiene xantohumol.
JPWO2004089359A1 (ja) * 2003-04-08 2006-07-06 麒麟麦酒株式会社 骨密度減少の抑制または予防用組成物および飲食品
DE102004063125B4 (de) * 2004-12-22 2007-03-15 Ta-Xan-Ag Natürlicher Xanthohumol-haltiger Extrakt sowie das Verfahren zu dessen Herstellung und daraus hergestellte Getränke
AU2006275491A1 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations
DE102006062264A1 (de) * 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
KR101323150B1 (ko) * 2011-04-25 2013-10-30 충남대학교산학협력단 잔토휴몰을 함유하는 골다공증 예방 및 치료용 조성물
CN103371989A (zh) * 2012-04-24 2013-10-30 华东师范大学 黄腐酚在制备抑制破骨细胞分化和蚀骨功能的预防和/或治疗药物中的应用
CA2880108C (en) * 2012-07-26 2021-05-18 Ta-Xan Ag Uses of compositions containing a roasted extract and xanthohumol
JP6009498B2 (ja) * 2014-06-24 2016-10-19 国立大学法人京都大学 アルツハイマー病予防薬
JP2018519342A (ja) 2015-07-02 2018-07-19 フラクサン ゲーエムベーハー ウント コー． カーゲー ホップに基づく物質およびその物質の使用
CN105477686B (zh) * 2015-11-30 2019-02-15 长春工业大学 一种包覆黄腐酚的纳米纤维膜

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794744A (en) * 1972-05-10 1974-02-26 White Tomkins Ltd Purification of hop extracts
US4065574A (en) * 1975-08-29 1977-12-27 The Upjohn Company New method for controlling fungi using 4-chromone, 4-chromanone, 4-chromone oxime and 4-chromanone oxime compounds

Also Published As

Publication number Publication date
HUT71603A (en) 1996-01-29
EP0679393B1 (en) 1998-01-14
ATE162073T1 (de) 1998-01-15
HU9501121D0 (en) 1995-06-28
EP0679393A2 (en) 1995-11-02
JPH07285856A (ja) 1995-10-31
TW284687B (es) 1996-09-01
US5679716A (en) 1997-10-21
AU1653595A (en) 1995-10-19
NO951498D0 (no) 1995-04-20
FI951856A (fi) 1995-10-22
NO951498L (no) 1995-10-23
AU695696B2 (en) 1998-08-20
DK0679393T3 (da) 1998-09-14
DE69501419T2 (de) 1998-06-25
EP0679393A3 (en) 1995-11-15
FI951856A0 (fi) 1995-04-19
DE69501419D1 (de) 1998-02-19
CA2147419A1 (en) 1995-10-22
KR100350564B1 (ko) 2002-12-16
KR950031060A (ko) 1995-12-18

Similar Documents

Publication Publication Date Title
ES2116642T3 (es) Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol.
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
BR0009830A (pt) Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
BR9206632A (pt) Sistema de penetração na pele melhorado para melhorada liberação tópica de drogas
DE69713485D1 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
ES2136139T3 (es) Componente farmaceutico de accion ralentizada que contiene acido bilico como componente activo.
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
ES2171669T3 (es) Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.
AR005969A1 (es) Procedimiento para preparar composiciones farmaceuticas que contienen benzotiofenos como agente activo, en unidades dosificadas o formulaciones de dosis multiple
PE20000644A1 (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
ES2106319T3 (es) Uso de lactoferrina en la fabricacion de un medicamento para el tratamiento del reumatismo.
AR002647A1 (es) Composiciones insecicidas que incluyen compuestos de 1-fenil o 1-piridin-2-il-pirazol como agente activo y procedimiento para combatir insectos con aplicación de dichas composiciones
PT1063969E (pt) Formulacao topica do tipo oleo-em-agua como um transportador para proporcionar um reduzido efeito de irritacao
RS50805B (sr) Upotreba fsh za lečenje neplodnosti
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.
ES2121109T3 (es) Composicion de champu.
ES2148268T3 (es) Composicion farmaceutica para prevenir o tratar fracturas de huesos.
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
AR004947A1 (es) Mezclas fungicidas sinergicas, procedimiento para obtener dichas mezclas y procedimiento para combatir hongos nocivos.
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 679393

Country of ref document: ES